Partnervest Advisory Services LLC Cuts Stake in Pfizer Inc. (PFE)

Partnervest Advisory Services LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 68.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,006 shares of the biopharmaceutical company’s stock after selling 15,024 shares during the quarter. Partnervest Advisory Services LLC’s holdings in Pfizer were worth $254,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Ballew Advisors Inc bought a new stake in shares of Pfizer in the 1st quarter valued at about $102,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of Pfizer in the 1st quarter valued at about $132,000. Braun Bostich & Associates Inc. bought a new stake in shares of Pfizer in the 1st quarter valued at about $139,000. Bray Capital Advisors bought a new stake in shares of Pfizer in the 1st quarter valued at about $139,000. Finally, Clearwater Capital Advisors LLC bought a new stake in shares of Pfizer in the 1st quarter valued at about $156,000. Hedge funds and other institutional investors own 69.03% of the company’s stock.

In other news, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Pfizer Inc bought 55,556 shares of the firm’s stock in a transaction dated Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the transaction, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The disclosure for this purchase can be found here. Insiders have sold a total of 234,096 shares of company stock valued at $9,366,617 in the last ninety days. 0.06% of the stock is currently owned by corporate insiders.



A number of research firms have recently weighed in on PFE. Goldman Sachs Group reissued a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research note on Tuesday, August 28th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Independent Research set a $48.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Thursday, October 4th. Credit Suisse Group boosted their target price on Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, August 1st. Finally, Barclays reissued a “neutral” rating and issued a $40.00 target price on shares of Pfizer in a research note on Wednesday, September 26th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $42.80.

PFE opened at $42.60 on Friday. The company has a market cap of $258.41 billion, a price-to-earnings ratio of 15.13, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. Pfizer Inc. has a one year low of $33.20 and a one year high of $45.81.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. Pfizer’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.67 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: Trading Strategy

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply